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For more than four decades, 5-fluorouracil (FU) has been the only
drug offering acceptable efficacy in the chemotherapeutic manage-
ment of colorectal cancer. More recently, the response rate of FU
has been shown to be markedly improved by combination with
folinic acid (FA) (Advanced Colorectal Cancer Meta-analysis
Project, 1992). 
There are currently new active anticancer drugs emerging in the
area of colorectal cancer treatment. Two drugs are of particular
interest: a new platinum derivative, oxaliplatin (LOHP) and a
camptothecin analogue, CPT11. LOHP as a single agent, shows
significant activity in colorectal cancer but, more interestingly, its
association with FUFA has been demonstrated to be superior to
FUFA in terms of antitumor efficacy in colorectal cancer (De
Gramont et al, 2000). These clinical results confirm previous
preclinical data indicating synergistic effects when combining
these drugs (Raymond et al, 1997; Fischel et al, 1998). In the same
way, CPT11 alone is active in colon cancer and, interestingly, in
patients refractory to FU (Cunningham et al, 1998; Rougier et al,
1998). More recently, it has been shown that the CPT11-FUFA
combination produced a higher response rate (Douillard et al,
2000; Saltz et al, 2000) and prolonged survival (Douillard et al,
2000) in comparison to FUFA in advanced colorectal cancer
patients. As for the LOHP–FUFA association, these clinical results
are in agreement with preclinical data showing synergistic interac-
tions between CPT11 and FUFA (Guichard et al, 2000; Pavillard et
al, 1998). 
This background survey invites consideration of a possible triple
combination involving CPT11, LOHP and FUFA. This association
is particularly justified by the specific differences in the respective
targets of drug action. The purpose of the present work was to
compare different schedules for the CPT11–LOHP–FUFA combi-
nation. Experimental conditions were established so as to adopt a
clinically relevant schedule and to take into account previous
experimental results (Fischel et al, 1998). To this end, the
LOHP–FUFA schedule was designed so as to reflect the widely
used ‘de Gramont’ protocol in which a 2 h LOHP sequence
precedes a 48 h FU exposure (De Gramont, 1997). SN38, the active
metabolite of CPT 11, was introduced into this fixed LOHP–FUFA
sequence thus giving rise to two different schedules in which SN38
was applied either before (schedule A) or after (schedule B) LOHP.
SN38 was used because CPT11 is inactive per se and needs to be
activated in the organism into SN38, the active drug (O’Reilly and
Rowinski, 1996). The study was undertaken on two human colon
cancer cell lines (WIDR and SW 620) that express spontaneous
sensitivity to the tested drugs. Both WIDR and SW 620 cells were
mutated for the p53 gene. We took tumour cell lines with p53 muta-
tions because a majority of human colorectal cancer carry a p53
mutational status (Kressner et al, 1999). 
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Chemicals 
All of the chemicals including MTT, l ascorbic acid, and dl
5-methyltetrahydrofolate were obtained from Sigma Chemical Co
(St Quentin Fallavier, France) and were of the highest purity avail-
able. Folic acid-free DMEM was obtained from Life Technologies,
Inc (Paisley, Scotland). Regular DMEM and glutamine were
obtained from Whittaker (Verviers, Belgium) and fetal bovine
serum from Dutscher (Brumath, France). Penicillin and strepto-
mycin were obtained from Merieux (Lyon, France). FU and LOHP
were the pharmaceutical forms obtained from Roche (Neuilly-sur-
Seine, France) and Sanofi Winthrop (Gentilly, France), respec-
tively. FA (pure l FA) was the pharmaceutical form obtained from
Wyeth-Lederle (Paris, France). SN 38 (7-ethyl-10-hydroxycamp-
tothecin) was provided by Rhone Poulenc Rorer (Paris, France). 
Cell lines 
Two colon cancer cell lines of human origin were used (Table 1).
Cells were routinely cultured in DMEM supplemented with 10%
fetal bovine serum, 2 mM glutamine, 50 000 U l21 penicillin and
80 µM streptomycin in a humidified incubator (Sanyo, Japan) at
37˚C with an atmosphere containing 8% CO2. One week before
experiments began, the cells were grown in a folate-controlled
medium (folic acid-free DMEM supplemented with 40 nM of dl
5-methyltetrahydrofolate and 0.1 mM of l ascorbic acid) to simu-
late as closely as possible the physiological situation encountered
in humans (Kones, 1990). The above folate-controlled medium
was used throughout the experiments. 
Evaluation of cytotoxicity 
Cells were seeded in 96-well microtitration plates (100 µl well21)
to obtain exponential growth for the whole duration of the experi-
ment (initial cell density was 3600 and 2500 cells well21 for
SW620 and WIDR, respectively). 24 h later, cells were exposed to
the drugs. We previously established that an optimal interaction
was obtained between SN38 and FUFA when SN38 was applied
before FUFA (Pavillard et al, 1998). In complement to these previ-
ously published data we made preliminary experiments so as to
select the drug sequence to be definitively tested in the present
study. We thus compared 5 different sequences on WIDR cells.
Sequence I with SN 38 (24 h) then medium during 24 h and then
LOHP (2 h) followed by FU (48 h); sequence II with SN 38 (24 h)
followed by LOHP (2 h) and then FU (48 h); sequence III with
LOHP (2 h) followed by SN 38 (24 h) and then FU (48 h);
sequence IV with LOHP (2 h) followed by FU (24 h) and then SN
38 and FU together during 24 h and sequence V with LOHP (2 h)
followed by FU (48 h) and then SN 38 (24 h). The decreasing
order of cytotoxic efficacy was as follows, I and III > II > IV >> V
as attested by the respective IC 50 values (mean  SD, n = 3) for
LOHP (µM), FU (µM) and SN 38 (µM) respectively: 
Sequence I: 5.2 6 1.2; 1.67 6 0.38; 0.83 6 0.19; 
Sequence II: 11.4 6 2.0; 3.65 6 0.64; 1.8 6 0.9; 
Sequence III: 7.6 6 1.8; 2.44 6 0.58; 1.2 6 0.28; 
Sequence IV: 15.6 6 4.1; 5.0  1.31; 2.5 6 0.66 and 
Sequence V: 22.1 6 3.1; 7.1 6 1.0; 3.5 6 0.5. 
Sequences I and III were thus kept for the definitive experiments;
they correspond to schedule A and schedule B, respectively (Figure
1). Pure l FA was always tested at 10 µM and did not exhibit any
effect on cell proliferation when tested alone. Concentration ranges
were as follows: 3 1027 M < (LOHP) < 3 1023 M; 9 10211 M <
(SN38) < 9 1027 M; 1.8 1027 M < (FU) < 1.8 1023 M. 11 concentra-
tions were tested for each drug. When combined, the drugs were
tested at a constant concentration ratio for a given cell line, the ratio
being dictated by the drug sensitivity and close to the ratio of the
IC50 of each drug (LOHP/SN38 ratios were 3320 and 6250 for
SW620 and WIDR respectively, those of LOHP/FU were 1.66 and
3.12, respectively). Experimental conditions were tested in sextupli-
cate (6 wells of the 96-well plate per experimental condition), and
experiments were performed at distance in triplicate. Growth inhibi-
tion was assessed by the MTT test (Carmichael et al, 1987) 120 h
after the start of drug exposure. Results were expressed as the
relative percentage of absorbance compared with controls without
drug. The dose–effect curves were analysed on Graphad Software
(Institute for Scientific Information, Philadelphia, PA). 
The cytotoxic effects obtained with the different drug combina-
tions were analysed according to the Chou and Talalay method
(1984) on Calcusyn software (Biosoft, Cambridge, United
Kingdom). For that purpose, FUFA was considered as a single
drug. Interaction between the 2 drugs or the 3 drugs together was
assessed by means of an automatically computed combination
index. Combination indexes were determined at 50% and 75% cell
lethality. Combination index is defined as follows: 
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Table 1 Cell line characteristics 
Cell line Origina P53 statusb FU IC50c (mean value, µM) LOHP IC50c (mean value, µM) SN38 IC50c (mean value, mM) 
SW620 ATCC (CCL 227) mutated 8.2 7.2 0.0036 
WIDR EORTC mutated 5.2 19.6 0.0039 
aATCC, American Type Culture Collection; EORTC, European Organization for Research and Treatment of Cancer. bP53 mutations were determined by
Dr P Laurent-Puig (INSERM U490, Paris). cIC50 means concentration inhibiting 50% of cell proliferation. See ‘Materials and Methods’ section for details on drug
exposure conditions. 
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Figure 1 Drug combinations tested on cell lines with CIA+B = combination index for a fixed effect (F) for the
combination of drug A and a drug B. 
DA/A+B = concentration of drug A in the combination A + B giving
an effect F. 
DB/A+B = concentration of drug B in the combination A + B giving
an effect F. 
DA = concentration of drug A alone giving an effect F. 
DB = concentration of drug B alone giving an effect F.
a = parameter with value 0 when A and B are mutually exclusive
and 1 when A and B are mutually non-exclusive. 
The combination index indicated synergism when smaller than
0.80, antagonism when greater than 1.20, and additive cytotoxic
effects when located between 0.80 and 1.20. 
Statistics 
Comparisons were performed on the whole cell line panel
by means of nonparametric ANOVA matched for cell lines and
experiments (Friedman test). Statistics were drawn up on SPSS
software (Chicago, IL). 
RESULTS 
Typical dose–effect curves for the different drug combinations are
displayed in Figure 2 for WIDR and Figure 3 for SW620. In all
cases, the conditions with all drugs applied together generated the
concentration–response curves at the left extremity meaning that
the best cytotoxic effects were obtained in these cases. 
The combination indexes (CI) computed at 50% and 75% cell
lethality are given in Table 2 for both cell lines. Based on these CI
values, it appears that the LOHP–FUFA combination was globally
synergistic, LOHP–SN38 either additive or antagonistic,
FUFA–SN38 antagonistic, and the triple combination resulted in
additive effects. Typical examples for CI/fractional effects curves
are given in Figures 4–6. 
The influence of the SN38 position in the triple combination was
further analysed by comparing the CI (Wilcoxon test matched for
cell lines, experiments and final cytotoxic effects). The observed
CI were significantly different according to the SN38 position
(P = 0.03), thus leading to a shift from a median value at 1.05 when
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Figure 2 In A and C, dose–effect curves of the different drugs tested alone ([: SN38; s s: FUFA u u: LOHP); in B and D, dose–effect curves of the drugs tested
in combination (l l: LOHP – FUFA; s: FUFA – SN38; u: LOHP – SN38; l: LOHP – FUFA – SN38). Figures 2A and 2B concern WIDR cell line exposed to
schedule A and Figures 2C and 2D concern WIDR cell line exposed to schedule B. The horizontal axis directly expresses the drug concentration for LOHP
(M/L). The tested SN38 concentration is obtained by dividing the reading concentration by 6250 and the tested FU concentration is obtained by dividing the
reading concentration by 3.12 582 J-L Fischel et al 
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Table 2 Combination indexes for the different drug associations 
Drug combination Sequence with SN38 % effect Combination indexesa
WIDR (mean ± SD) SW620 (mean ± SD) General pattern 
LOHP-FUFA 50 0.60 ± 0.20 0.85 ± 0.13 Synergistic 
75 0.45 ± 0.31 0.70 ± 0.24
r ± SDb 0.992 ± 0.004 0.982 ± 0.030
LOHP-SN38 Schedule A (without FU) 50 1.60 ± 0.16 1.45 ± 0.31 Additive or antagonistic
75 1.35 ± 0.50 1.13 ± 0.21
r ± SD 0.993 ± 0.005 0.979 ± 0.026
Schedule B (without FU) 50 1.23 ± 0.13  1.00 ± 0.10
75 1.20 ± 0.19 1.10 ± 0.18
r ± SD 0.992 ± 0.004 0.991 ± 0.005 
FUFA-SN38 Schedule A (without LOHP) 50 1.55 ± 0.21 1.43 ± 0.64 Antagonistic 
75 1.28 ± 0.26 1.00 ± 0.45 
r ± SD 0.987 ± 0.007 0.986 ± 0.009 
Schedule B (without LOHP) 50 2.22 ± 2.45 1.20 ± 0.61 
75 2.00 ± 1.12 1.70 ± 0.57 
r ± SD 0.978 ± 0.020 0.981 ± 0.017 
SN38-LOHP-FUFA Schedule A (all drugs) 50 1.00 ± 0.36 0.93 ± 0.22 Additive 
75 0.80 ± 0.13 0.78 ± 0.15
r ± SD 0.992 ± 0.004 0.988 ± 0.014 
Schedule B (all drugs) 50 1.43 ± 0.68 0.985 ± 0.30 
75 1.10 ± 0.13 1.10 ± 0.32 
r ± SD 0.991 ± 0.007 0.985 ± 0.007 
Schedule A corresponds to the sequence where SN 38 is applied first and schedule B corresponds to the sequence where SN 38 is applied after LOHP (see
Figure 1 for details); a: Combination indexes (CI), computed according to the Chou and Talalay method (Calculsyn Software), indicated synergism when smaller
than 0.80, antagonism when greater than 1.20, and nearly additivity between 0.80 and 1.20; b: r value is the coefficient of correlation for the fitting between CI
values and fractional effects (5 to 7 experimental points between 0.2 and 1.0); SD means standard deviation. For the triple association (SN 38 – LOHP – FUFA)
the CIs are computed by taking into account the dose-response curves of each individual drug. 
Figure 3 In A and C, dose–effect curves of the different drugs tested alone ([: SN38; s s: FUFA; u u: LOHP); in B and D dose–effect curves of the drugs tested
in combination (l l: LOHP – FUFA; s: FUFA – SN38; u: LOHP – SN38; l: LOHP – FUFA – SN38). Figures 3A and 3B concern SW620 cell line exposed to
schedule A and Figures 3C and 3D concern SW 620 cell line exposed to schedule B. The horizontal axis directly expresses the drug concentration for LOHP
(M/L). The tested SN38 concentration is obtained by dividing the reading concentration by 3320 and the tested FU concentration is obtained by dividing the
reading concentration by 1.66 
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SW620SN38 was applied after LOHP (1st–3rd quartile 0.90–1.38, range
0.70–2.40) to a median value at 0.80 when SN38 was applied first
(1st–3rd quartile 0.70–1.00, range 0.60–1.50). Comparison of the CI
resulting from the triple association (additivity pattern) with the CI
resulting from the LOHP–FUFA association (synergistic pattern)
indicates that the presence of SN38 does not add to the cytotoxicity
already confered by the LOHP–FUFA combination (Table 2). 
The relative contribution of each drug to the overall cytotoxicity
of the triple combination was then analysed by computing the ratio
defined as the drug concentration giving 50% of cell lethality
(IC50) of the double association without that drug divided by the
IC50 of the triple association (the higher the ratio, the greater
the contribution of that given drug). Table 3 gives the values of
relative contributions for SN38, FUFA and LOHP. Statistical
analysis (Friedman test paired on cell lines, experiments and
schedules) indicated that relative contributions of each of the 3
drugs are significantly different (P = 0.002, first line Table 3).
Whatever the SN38 position, the greater contribution to the overall
cytotoxicity of the triple combination comes from LOHP (median
relative contribution = 2.4) and the smallest comes from SN38
(median relative contribution = 1.1). This analysis confirms that
SN38 brings a relatively modest contribution to the cytotoxicity of
the triple association. Interestingly, when considering schedules A
and B separately, SN38 and LOHP relative contributions remained
similar whereas the relative contribution of FUFA improved
considerably when SN38 was applied first (Table 3). 
Of note, when considering the results obtained from both cell
lines (Figures 2 and 3, Table 2) it can be observed that a close
agreement does exist between them. 
DISCUSSION 
Given the recent clinical data in gastrointestinal cancer showing
the very promising antitumour effects produced by combinations
of LOHP and FUFA (De Gramont et al, 2000) and of CPT 11 and
FUFA (Douillard et al, 2000), it is likely that the triple association
between LOHP, CPT 11 and FUFA will soon be tested in cancer
patients. Since each drug has its own significant toxicity, it is
important to learn, at an experimental stage, what type of interac-
tion might result from the combined effects of these three drugs.
Answering this question was the central goal of the present study.
In order to minimize the inevitable discrepancy between conclu-
sions at the bench and clinical applications at the bedside, the drug
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Table 3 Relative contributions of each drug to the overall cytotoxicity of the triple associationa
SN38 contribution FUFA contribution LOHP contribution Statisticsb
Whatever median 1.12 1.59 2.42 P = 0.002
the schedule 1st–3rd quartile 0.95–1.58 1.12–2.62 1.47–3.88 
Schedule A median 1.16 2.24 2.42 P = 0.002 
1st–3rd quartile 0.98–1.57 1.35–2.67  1.53–4.13
Schedule B median 1.12 1.23 2.46 P = 0.32
1st–3rd quartile 0.90–1.65 1.03–1.88  1.06–3.88 
Data are averaged values by grouping the results of WIDR with those of SW 620. aThe relative contribution of each drug was defined as the IC50 of the double
association without that drug divided by the IC50 of the triple association (a ratio at 1 indicated no contribution at all). bComparison of the relative contributions
of SN38, FUFA and LOHP according to the Friedman test, paired on cell lines and experiments. 
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Figure 6 Typical combination index/fractional effect curve derived from Chou
and Talalay model: SN 38 – LOHP – FUFA, schedule B, WIDR cells (globally
antagonist) combinations were tested by applying clinically compatible condi-
tions. Most similar in vitro studies are often based on the use of a
single tumour cell line. In the present work two p53 mutated
human colon cancer cell lines were investigated and, interestingly,
results globally concur fairly well between cell lines (Tables 2 and
4). This fact strengthens the impact of the present observations. 
Analysis of the double association LOHP–FUFA showed a
majority of synergistic interactions (Table 2). This corroborates
previous results by others (Raymond et al, 1998) and us (Fischel
et al, 1998). Such synergism could be related to the previously
demonstrated reduced folate pool expansion under the effects of
platinum derivatives (Scanlon et al, 1986; Shirasaka et al, 1993).
In addition, recent pharmacokinetic data have suggested that
LOHP can inhibit dihydropyrimidine dehydrogenase (DPD) which
is the rate-controlling enzyme of FU catabolism (Gamelin et al,
1997), and that this DPD inhibition may enhance FUFA cytotoxi-
city (Milano and Etienne, 1994). 
When examining the effects of the FUFA–SN38 combination,
antagonistic effects were observed (Table 2). This observation
differs from previous results showing synergism when applying
SN38 before FUFA (Pavillard et al, 1998). A reason for this
discrepency may lie in the different tested schedules, SN38–FUFA
combination having been previously tested as two 48 h consecu-
tive sequence for each drug, whereas in the present study a 24 h
sequence was applied for SN38 and a 48 h sequence for FU. 
The combination of LOHP and CPT11 was tested in early clinical
investigations (Wasserman et al, 1999; Scheithauer et al, 1999).
Interactions between the two drugs have been studied at pharmaco-
kinetic level without evidence of noticeable modifications in the
pharmacokinetics of each drug (Lokiec et al, 1997). Present data
indicate that the association of SN38 and LOHP does not produce
synergistic effects but, on the contrary, triggers mild antagonism
(when SN38 is applied first) or additivity (when SN38 is applied
after LOHP, Table 2). The present results differ from that recently
obtained on the HT 29 colon cancer cell line (Zeghari-Squalli et al,
1999); the authors found a synergy when LOHP and SN38 were
combined, SN 38 being applied with LOHP or before and after
LOHP. The discrepency between the present results and those
reported by Zeghari-Squalli and coworkers (1999) may be
explained by the HT 29 cell line used by these later authors which is
100 fold less sensitive to SN38 than the cell lines investigated in the
present study; another difference is the long exposure time to LOHP
(24 h) which was applied by these authors as compared to the condi-
tions of present study (LOHP, 2 h). In addition, pharmacological
interactions may exist between these two drugs since irinotecan-
related cholinergic syndrome has been reported to be induced by the
coadministration of oxaliplatin (Valencak et al, 1998). 
When SN38, LOHP and FUFA were combined, the position of
SN38 had a significant influence on the CI, leading to a shift from
additivity-antagonism when SN38 was applied after LOHP
(schedule B), towards additivity-synergism when SN38 was
applied first (schedule A, Table 2). Importantly, examination of the
relative contributions of each of the 3 drugs in the resulting global
cytotoxicity reveals that the contribution of FUFA was clearly
two-fold greater in schedule A (median 2.24) as compared with
schedule B (median 1.23), whereas the relative contributions of
SN38 and LOHP were not modified (Table 3). Moreover, addi-
tional cytometry analyses performed in the present study demon-
strated that SN38 significantly induced cell recruitment in the
S-G2-M phases 24 h and 48 h after SN38 exposure (unshown
data). Also, the impact of camptothecins on the cell cycle was
previously reported by others (Goldwasser et al, 1996) and
ourselves (Pavillard et al, 1998). Since FU acts preferentially on
cells entering the S phase, all together these data indicate that the
SN38 position significantly influences the cytotoxicity of FUFA:
in schedule A, FU was applied 26 h after the end of SN38 expo-
sure, at the time of S phase recruitment, thus leading to greater FU
cytotoxic effects as compared to schedule B. 
Importantly, this study clearly demonstrates that the drug
which makes the greatest contribution in the triple combination is
LOHP (median relative contribution around 2.4) in contrast to
SN38 which, in comparison, brings a relatively modest contribu-
tion (median relative contribution around 1.1, Table 3). The clin-
ical application of the ternary combination considered in the
present study may lead to a combined toxicity in treated patients.
As recently stressed by Ratain (1999), original associations of
drugs should be first tested at experimental level before clinical
trials are begun. The present results may help to objectively
discuss the rationale of future clinical trials combining CPT11,
LOHP and FU. 
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